LSD is not an amphetamine. The two drugs come from entirely different chemical families, act on different brain systems, and produce experiences that bear little resemblance to each other. The confusion is understandable, though, because a handful of amphetamine-based compounds do produce hallucinogenic effects, blurring the line between “stimulant” and “psychedelic” in ways that can mislead anyone who hasn’t looked closely at the chemistry.
Why They Belong to Different Chemical Families
Psychedelic drugs fall into three broad structural classes: tryptamines, ergolines, and phenethylamines. LSD is an ergoline, originally derived from compounds in the ergot fungus and then heavily modified through laboratory chemistry. Amphetamine and its relatives, by contrast, belong to the phenethylamine class, built around a simpler scaffold of a benzene ring with an amino group attached through a short carbon chain.1PubMed Central. Psychedelics The two molecules look nothing alike on paper, and this structural difference is not a technicality. It determines which receptors each drug binds to, how long it stays active in your body, what kind of experience it creates, and what risks it carries.
Amphetamine’s core job is to flood the brain with dopamine and norepinephrine, the chemicals behind feelings of energy, focus, and reward. LSD’s main target is the serotonin system, especially a receptor called 5-HT2A, which is central to perception, mood, and the kind of reality-bending experiences psychedelics are known for. LSD does also bind to dopamine D1 and D2 receptors, which may contribute to some of its stimulant-like qualities like wakefulness and restlessness, but this dopamine activity is a side note rather than the main event.2SpringerOpen. Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD
The Confusing In-Between: Hallucinogenic Amphetamines
If LSD and amphetamine are so different, why does the question come up at all? Partly because there is a genuine gray zone. Several drugs built on amphetamine’s backbone have been modified to produce hallucinogenic effects. Compounds like DOM, DOI, and DOB are chemically classified as amphetamine derivatives, yet they act primarily on serotonin 5-HT2A receptors and produce vivid visual distortions and altered states of consciousness rather than the clean stimulant rush of plain amphetamine.3PubMed. Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat MDMA (ecstasy) is another amphetamine derivative that sits in between, releasing both serotonin and dopamine while producing empathogenic and mildly psychedelic effects.4Biochemical Pharmacology. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain
These hybrid drugs show that the stimulant-psychedelic boundary is messier than a clean two-category split. But LSD itself is not part of this gray zone. It did not evolve from the amphetamine molecule. It sits in the ergoline class alongside other ergot-derived compounds, and the fact that some amphetamine derivatives can mimic certain psychedelic effects does not make LSD one of them, any more than the existence of flying fish makes a trout a bird.
What Each Drug Actually Feels Like
A clinical study that gave healthy volunteers LSD, MDMA, and d-amphetamine in separate sessions under controlled conditions found dramatic differences in subjective experience. LSD was the only substance that induced large-scale alterations of consciousness, producing high scores across every dimension of a standardized altered-states questionnaire. Participants reported pronounced ego dissolution, warped sense of time, emotional intensity, and vivid perceptual changes that neither MDMA nor d-amphetamine came close to matching.5PubMed Central. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects MDMA produced some increase in feelings of bliss but little else on the altered-states scale. D-amphetamine had no significant effect on any altered-consciousness measure at all.6Neuropsychopharmacology. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
The pattern ran in the other direction for functional qualities. D-amphetamine increased participants’ self-rated activity and concentration, while LSD impaired both. People on LSD felt introverted, anxious, and mentally slower; people on amphetamine felt energized and sharp.5PubMed Central. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects In short, the two drugs push the mind in almost opposite directions: amphetamine narrows and focuses attention, while LSD pries it open and scrambles the usual filters.
Physical Effects on the Heart and Body
Both LSD and amphetamine rev up the cardiovascular system, but they do it differently. In the same head-to-head study, d-amphetamine raised blood pressure significantly more than LSD did, while LSD and MDMA pushed heart rate up more than d-amphetamine in the first four hours. When researchers looked at overall cardiovascular strain using a combined measure of heart rate and blood pressure, all three substances produced roughly similar levels of hemodynamic stimulation. All three also dilated the pupils.6Neuropsychopharmacology. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
LSD’s cardiac effects go beyond simple stimulation. Hallucinogenic drugs broadly can increase the force and rate of heart contractions, and in some cases trigger abnormal heart rhythms.7PubMed Central. Effects of hallucinogenic drugs on the human heart These effects are driven largely through serotonin receptor activity in heart tissue rather than through the adrenaline-like pathway that amphetamines use. The practical difference matters for anyone with pre-existing cardiac conditions: the specific receptor systems each drug activates create different risk profiles even when the headline numbers on blood pressure and heart rate look comparable.
One other physical detail from the clinical trial: LSD was the only substance that significantly increased the total score of acute adverse effects compared with placebo. The most commonly reported complaints included headache, dizziness, and nausea. No severe adverse events were observed with any of the three drugs during the study.6Neuropsychopharmacology. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Why LSD Lasts So Long Compared to Amphetamine
A standard amphetamine dose wears off in roughly four to six hours. An LSD trip typically lasts eight to twelve. Part of the reason for this gap is that LSD clings to its target serotonin receptors with unusual tenacity. Researchers who solved the crystal structure of LSD bound to a serotonin receptor discovered that once LSD slots into the binding pocket, a piece of the receptor folds over the molecule like a lid, trapping it in place. This “lid” mechanism means LSD dissociates from both the 5-HT2B and 5-HT2A receptors exceptionally slowly, keeping the drug active long after it would otherwise have been cleared.8PubMed Central. Crystal Structure of an LSD-Bound Human Serotonin Receptor Amphetamine, by contrast, works more like an open faucet: it floods the synapse with dopamine and norepinephrine, and the effect fades as the brain clears those neurotransmitters. There is no lid to hold the process in place.
Tolerance and Addiction Risk
These two drugs behave very differently when it comes to repeated use. LSD builds tolerance remarkably fast. Noticeable tolerance appears within 24 hours of a single dose and reaches its peak by about the fourth day. Once full tolerance sets in, even quadrupling the dose fails to overcome it. The tolerance also generalizes to other serotonergic psychedelics like psilocybin and mescaline, but critically, it does not generalize to amphetamine. Someone tolerant to LSD’s effects still responds normally to amphetamine, and vice versa, which is further evidence that the two drugs operate through separate receptor systems.9ScienceDirect. Tolerance to Lysergic Acid Diethylamide: Overview, Correlates, and Clinical Implications
This rapid tolerance is actually one reason LSD carries low addiction potential. Because the effects diminish so quickly with repeated use, there is a built-in brake against the kind of escalating, compulsive dosing that characterizes addiction. You cannot chase the high the way you can with stimulants. Amphetamines, on the other hand, are well-established drugs of abuse. They activate the brain’s reward circuitry in a direct, reinforcing way, tolerance develops more gradually, and people can fall into patterns of escalating use. This is not to say LSD is harmless or consequence-free, but the specific pharmacological loop that drives addiction with stimulants simply does not apply.
How They Reshape Brain Networks
Brain imaging studies add another layer of distinction. A study that directly compared LSD, d-amphetamine, and MDMA using large-scale brain connectivity analysis found that while all three substances disrupted normal brain network organization, they did so in markedly different ways. LSD uniquely reduced the integrity of the default-mode network, the system associated with your sense of self and internal narrative. This disruption likely underlies the ego dissolution and boundary-blurring that LSD users describe.10PubMed Central. Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine
The amphetamines actually reduced integrity in more networks overall than LSD did, which surprised the researchers. But the quality of the disruption differed. LSD’s effects on network segregation were characterized entirely by decreases, meaning it broke down the usual walls between brain regions, allowing them to “talk” to each other more freely. The amphetamines showed a mix of increases and decreases, a less uniform reshuffling. LSD also specifically increased connectivity in the basal ganglia and thalamus, deep brain structures involved in sensory gating and movement, while all three substances decreased connectivity in visual areas.10PubMed Central. Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine The takeaway is that even where these drugs produce superficially similar-sounding effects on brain activity, the underlying network changes are qualitatively different.
Drug Testing and Why LSD Won’t Trigger an Amphetamine Screen
Standard drug-of-abuse screening in hospitals and workplaces relies on immunoassays, antibody-based tests designed to detect specific chemical classes like amphetamines, opiates, benzodiazepines, and cocaine. These tests work by recognizing structural features shared among drugs in the same family. Because LSD’s ergoline structure is chemically unrelated to amphetamine’s phenethylamine backbone, an amphetamine immunoassay will not flag LSD.11PubMed Central. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine
LSD is also notoriously difficult to detect on any screening panel because it is taken in microgram quantities, far smaller than the milligram doses typical of most drugs. By the time a test is administered, the tiny amount of LSD and its metabolites may already be below the detection threshold. Specialized assays exist, but they are not part of the standard panel and are rarely ordered unless there is a specific clinical reason to look for LSD. The two drugs inhabit completely separate lanes in forensic toxicology, just as they do in pharmacology.
Designer Derivatives That Blur the Lines Further
The emergence of so-called designer psychedelics has added another layer of confusion. Compounds like 1P-LSD, ALD-52, and 1B-LSD are modified versions of the LSD molecule, typically with an extra chemical group tacked onto the indole nitrogen. These substances have appeared in online markets, sometimes sold in legal gray areas where the parent compound is banned. Research on these derivatives has shown that they function as prodrugs: once ingested, the body rapidly strips off the added chemical group and converts them into plain LSD. In animal studies, high levels of LSD appeared in blood plasma after administration of ALD-52 and 1P-LSD, confirming efficient conversion.12PubMed Central. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)
None of these are amphetamine-based. They are all ergolines, tweaked versions of LSD’s own structure. Their existence in unregulated markets alongside amphetamine-derived psychedelics like DOx compounds and NBOMe substances can contribute to the public perception that all these drugs are somehow in the same chemical family. They are not. But if you encounter an unfamiliar substance sold as a “research chemical” or “legal alternative,” the label alone tells you very little about what class of drug you are actually dealing with.
Microdosing Versus Stimulant Medications for ADHD
One area where LSD and amphetamines are increasingly mentioned in the same breath is attention-deficit hyperactivity disorder. Standard ADHD medications are often amphetamine-based (like Adderall) or closely related stimulants. Some people with ADHD have turned to microdosing psychedelics, typically LSD or psilocybin, as an alternative. The idea is that a sub-perceptual dose might improve focus and emotional regulation without the side effects of stimulant medication.
Early naturalistic data looked promising. A comparison study found that adults with severe ADHD symptoms who microdosed psychedelics showed lower symptom scores at four weeks than those taking conventional ADHD medication.13PubMed Central. Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation, empathy, and ADHD symptoms in adults with severe ADHD symptoms But a more rigorous Phase 2A trial that specifically tested LSD microdosing against placebo over six weeks found no significant benefit. Both groups improved substantially, suggesting the gains were driven by placebo effects rather than the drug itself.14The Brown University Psychopharmacology Update. Microdosing of LSD does not show efficacy in adults with ADHD The discrepancy between the open-label data and the placebo-controlled trial is a familiar pattern in psychedelic research, where expectation effects tend to be unusually strong. As of now, there is no solid clinical evidence that microdosing LSD replicates or replaces what amphetamine-based ADHD medications do, and the mechanisms by which each approach might help are fundamentally different anyway: stimulants boost dopamine tone directly, while the hypothesized microdosing benefit, if it exists, would presumably work through serotonergic pathways that regulate emotional flexibility and cognitive style rather than raw attentional drive.
Why the Confusion Persists
Several forces keep this question alive. Street-level drug culture often lumps substances together by their legal status rather than their chemistry, and both LSD and amphetamines have spent decades in the same Schedule I or equivalent categories in most countries. The existence of genuinely hybrid molecules like DOM and MDMA, which are structurally amphetamines but pharmacologically closer to the psychedelic or empathogen world, muddies the water further. And the physiological overlap is real in a superficial sense: both LSD and amphetamine raise your heart rate, dilate your pupils, and keep you awake. If you are only looking at a person’s vital signs in an emergency room, the two can look more alike than they actually are.
But the similarities end there. The chemical structures are different. The primary receptor targets are different. The subjective experience is different. The tolerance patterns are different. The addiction potential is different. The brain network signatures are different. And the drug-testing profiles are different. LSD and amphetamine are about as closely related as coffee and psilocybin mushrooms, which is to say they share the broad category of “psychoactive substance” and not much else.